BridgeBio Pharma, Inc. Ttl Fee Amt
BridgeBio Pharma, Inc. (BBIO) had Ttl Fee Amt of $22.31 thousand as of 2026-07-24, per its S-8 filed 2026-07-24.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-07-24
- 2026-07-24: Ttl Fee Amt $22.31K.
- 2026-05-08: Ttl Fee Amt $69.05K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-07-24 | $22.31K S-8 · filed 2026-07-24 |
| 2026-05-08 | $69.05K S-3ASR · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |